363 related articles for article (PubMed ID: 21411714)
21. Overcoming Multidrug Resistance by Codelivery of MDR1-Targeting siRNA and Doxorubicin Using EphA10-Mediated pH-Sensitive Lipoplexes: In Vitro and In Vivo Evaluation.
Zhang J; Du Z; Pan S; Shi M; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X
ACS Appl Mater Interfaces; 2018 Jun; 10(25):21590-21600. PubMed ID: 29798663
[TBL] [Abstract][Full Text] [Related]
22. Theranostic Nanoprobe Mediated Simultaneous Monitoring and Inhibition of P-Glycoprotein Potentiating Multidrug-Resistant Cancer Therapy.
Wei Y; Xia H; Zhang F; Wang K; Luo P; Wu Y; Liu S
Anal Chem; 2019 Sep; 91(17):11200-11208. PubMed ID: 31403276
[TBL] [Abstract][Full Text] [Related]
23. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
[TBL] [Abstract][Full Text] [Related]
24. Reversing P-Glycoprotein-Associated Multidrug Resistance of Breast Cancer by Targeted Acid-Cleavable Polysaccharide Nanoparticles with Lapatinib Sensitization.
Sui J; He M; Yang Y; Ma M; Guo Z; Zhao M; Liang J; Sun Y; Fan Y; Zhang X
ACS Appl Mater Interfaces; 2020 Nov; 12(46):51198-51211. PubMed ID: 33147005
[TBL] [Abstract][Full Text] [Related]
25. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
[TBL] [Abstract][Full Text] [Related]
26. Contribution of carboxyl modified chiral mesoporous silica nanoparticles in delivering doxorubicin hydrochloride in vitro: pH-response controlled release, enhanced drug cellular uptake and cytotoxicity.
Li J; Du X; Zheng N; Xu L; Xu J; Li S
Colloids Surf B Biointerfaces; 2016 May; 141():374-381. PubMed ID: 26878288
[TBL] [Abstract][Full Text] [Related]
27. Polydopamine coated hollow mesoporous silica nanoparticles as pH-sensitive nanocarriers for overcoming multidrug resistance.
Shao M; Chang C; Liu Z; Chen K; Zhou Y; Zheng G; Huang Z; Xu H; Xu P; Lu B
Colloids Surf B Biointerfaces; 2019 Nov; 183():110427. PubMed ID: 31408782
[TBL] [Abstract][Full Text] [Related]
28. Alisol F 24 Acetate Enhances Chemosensitivity and Apoptosis of MCF-7/DOX Cells by Inhibiting P-Glycoprotein-Mediated Drug Efflux.
Pan G; Li T; Zeng Q; Wang X; Zhu Y
Molecules; 2016 Feb; 21(2):. PubMed ID: 26861264
[TBL] [Abstract][Full Text] [Related]
29. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy.
Zhang CG; Zhu WJ; Liu Y; Yuan ZQ; Yang SD; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN
Sci Rep; 2016 Mar; 6():23859. PubMed ID: 27030638
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin and adjudin co-loaded pH-sensitive nanoparticles for the treatment of drug-resistant cancer.
Wang Q; Zou C; Wang L; Gao X; Wu J; Tan S; Wu G
Acta Biomater; 2019 Aug; 94():469-481. PubMed ID: 31141733
[TBL] [Abstract][Full Text] [Related]
31. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
32. Novel virosecurinine bivalent mimetics as potent reversal agents against P-glycoprotein-mediated multidrug resistance.
Hou W; Meng Y; Xu XF; Huang ZX; Liu J; Wang ZY; Lin J; Chen WM
Eur J Med Chem; 2019 Dec; 183():111726. PubMed ID: 31585275
[TBL] [Abstract][Full Text] [Related]
33. A Y
Wang Y; Jiang Z; Yuan B; Tian Y; Xiang L; Li Y; Yang Y; Li J; Wu A
Biomater Sci; 2019 Nov; 7(11):4748-4757. PubMed ID: 31508613
[TBL] [Abstract][Full Text] [Related]
34. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
35. Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter.
Seebacher NA; Lane DJ; Jansson PJ; Richardson DR
J Biol Chem; 2016 Feb; 291(8):3796-820. PubMed ID: 26601947
[TBL] [Abstract][Full Text] [Related]
36. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.
Pan ZZ; Wang HY; Zhang M; Lin TT; Zhang WY; Zhao PF; Tang YS; Xiong Y; Zeng YE; Huang YZ
Acta Pharmacol Sin; 2016 Aug; 37(8):1110-20. PubMed ID: 27292613
[TBL] [Abstract][Full Text] [Related]
37. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells.
Zhou S; Wu D; Yin X; Jin X; Zhang X; Zheng S; Wang C; Liu Y
J Exp Clin Cancer Res; 2017 Feb; 36(1):24. PubMed ID: 28166836
[TBL] [Abstract][Full Text] [Related]
38. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.
Leontieva OV; Preobrazhenskaya MN; Bernacki RJ
Invest New Drugs; 2002 Feb; 20(1):35-48. PubMed ID: 12003193
[TBL] [Abstract][Full Text] [Related]
39. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
40. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
